1.
HIV-1 group P infection: towards a dead-end infection?
by Alessandri-Gradt, Elodie
AIDS (London), 2018, Vol.32 (10), p.1317-1322
2.
First evidence of transmission of an HIV-1 M/O intergroup recombinant virus
by Ngoupo, Paul Alain
AIDS (London), 2016, Vol.30 (1), p.1-8
3.
Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis
by Hemelaar, Joris
The Lancet infectious diseases, 2018
4.
Defining HIV-1 transmission clusters based on sequence data
by Hassan, Amin S
AIDS (London), 2017, Vol.31 (9), p.1211-1222
5.
Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis
by Donnell, Deborah, Dr
The Lancet (British edition), 2010, Vol.375 (9731), p.2092-2098
6.
The rapidly expanding CRF01_AE epidemic in China is driven by multiple lineages of HIV-1 viruses introduced in the 1990s
by Feng, Yi
AIDS (London), 2013, Vol.27 (11), p.1793-1802
7.
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-in...
by Raffi, François, Prof
The Lancet infectious diseases, 2013, Vol.13 (11), p.927-935
8.
The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption
by Li, Jonathan Z
AIDS (London), 2016, Vol.30 (3), p.343-353
9.
Nationwide trends in molecular epidemiology of HIV-1 in China
by Li, Xiaoshan
AIDS research and human retroviruses, 2016, Vol.32 (ja), p.851-859
10.
Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial
by Lester, Richard T, Dr
The Lancet (British edition), 2010, Vol.376 (9755), p.1838-1845
11.
A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus
by Thompson, Melanie
AIDS (London), 2016, Vol.30 (6), p.869-878
12.
Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960
by Kabongo, Jean-Marie M
Nature, 2008, Vol.455 (7213), p.661-664
13.
Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease
by Tebit, Denis M, PhD
The Lancet infectious diseases, 2011, Vol.11 (1), p.45-56
14.
Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004
by HEMELAAR, Joris
AIDS (London), 2006, Vol.20 (16), p.W13-W23
15.
Large cluster outbreaks sustain the HIV epidemic among MSM in Quebec
by Brenner, Bluma G
AIDS (London), 2017, Vol.31 (5), p.707-717
16.
Gut microbiota diversity predicts immune status in HIV-1 infection
by Nowak, Piotr
AIDS (London), 2015, Vol.29 (18), p.2409-2418
17.
Four-class drug-resistant HIV-1 subtype C in a treatment experienced individual on dolutegravir-based antiretroviral therapy in Botswana
by Seatla, Kaelo K
AIDS (London), 2018, Vol.32 (13), p.1899-1902
18.
Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy
by HUNT, Peter W
AIDS (London), 2011, Vol.25 (17), p.2123-2131
19.
Recombination analysis of near full-length HIV-1 sequences and the identification of a potential new Circulating Recombinant Form from Rakai, Uganda
by Capoferri, Adam A
AIDS research and human retroviruses, 2020, Vol.36 (ja), p.467-474
20.
Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34 + cells
by Mitsuyasu, Ronald T
Nature medicine, 2009, Vol.15 (3), p.285-292
